VSTM Verastem Inc.

1.28
-0.01  -1%
Previous Close 1.29
Open 1.3
Price To Book 1.91
Market Cap 94,900,079
Shares 74,140,687
Volume 678,590
Short Ratio
Av. Daily Volume 1,872,657

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 presentation ASCO June 2018.
Duvelisib
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
FDA Approval announced September 24, 2018.
Duvelisib - DUO
Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
VS-6063
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Edited Transcript of VSTM earnings conference call or presentation 1-Aug-19 8:30pm GMT
  2. Verastem Inc (VSTM) Q2 2019 Earnings Call Transcript
  3. Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates
  4. Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
  5. The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings
  6. Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer
  7. The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint
  8. Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa
  9. Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019
  10. What Kind Of Shareholders Own Verastem, Inc. (NASDAQ:VSTM)?
  11. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  12. Hedge Funds Have Never Been This Bullish On Verastem Inc (VSTM)
  13. Verastem Up on Positive Data From Early-Stage Copiktra Study
  14. Verastem Shares Response Rate From COPIKTRA Data
  15. Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma
  16. The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
  17. Verastem Oncology Announces Leadership Changes
  18. Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting
  19. Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference
  20. Did You Manage To Avoid Verastem's (NASDAQ:VSTM) Devastating 85% Share Price Drop?